We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
FDA Expands Age Range for Shingles Vaccine.
- Authors
Voelker, Rebecca
- Abstract
The article reports on the U.S. Food and Drug Administration's (FDA) approval of the expanded age range for the shingles vaccine marketed as Zosvatax in March 2011. The vaccine has been made available for adults aged 50 to 59 years and for those aged 60 years and older. A multicenter study in the U.S. and other countries showed that the vaccine reduced the risk of developing shingles in the elderly by about 70 percent. Zosvatax, manufactured by Merck & Co. Inc., was initially licensed in 2006 for adults aged 60 years and older.
- Subjects
HERPES zoster vaccines; IMMUNIZATION of older people; VACCINATION; MERCK &; Co. Inc.; GERIATRICS -- Immunological aspects; PREVENTIVE health services for older people
- Publication
JAMA: Journal of the American Medical Association, 2011, Vol 305, Issue 15, p1526
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2011.495